drugset
drugset / Trial / NCT05776862

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

NCT05776862 ↗

Phase 2 Completed 10 enrolled University of Miami Florida · collab
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.

Timeline

Start
2023-03-27
Primary completion
2025-01-29
Completion
2025-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursolic Acid Small molecule 400 mg Oral

Indications

muscular atrophy paraplegia quadriplegia spinal cord injury